IDH1 and central nervous system cancer: In contrast to a median overall survival of 34.6 months for IDH1‐wildtype (IDH1‐WT) patients with histologically low‐grade glioma (LGG), this value was determined to be 76.0 months for IDH1‐mutant (IDH1‐MUT) LGG patients.[4] Despite the overarching goal of maximal safe resection, surgical approaches differ significantly between IDH1 subtypes.